Insider Transactions in Q1 2024 at Precision Biosciences Inc (DTIL)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 29
2024
|
John Alexander Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
506
+2.36%
|
$9,108
$18.5 P/Share
|
|
Feb 29
2024
|
J. Jefferson Smith Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,006
+1.47%
|
$12,072
$12.42 P/Share
|
|
Jan 23
2024
|
J. Jefferson Smith Chief Research Officer |
SELL
Open market or private sale
|
Direct |
28,000
-1.39%
|
$0
$0.37 P/Share
|
|
Jan 22
2024
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
21,287
-12.35%
|
$0
$0.36 P/Share
|
|
Jan 22
2024
|
Michael Amoroso President and CEO |
SELL
Open market or private sale
|
Direct |
137,390
-27.82%
|
$0
$0.36 P/Share
|
|
Jan 22
2024
|
Alan List Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,526
-18.48%
|
$0
$0.36 P/Share
|
|
Jan 20
2024
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
59,345
+25.62%
|
-
|
|
Jan 20
2024
|
Michael Amoroso President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
266,720
+35.07%
|
-
|
|
Jan 20
2024
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
116,690
+15.97%
|
-
|
|
Jan 20
2024
|
J. Jefferson Smith Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,015
+3.59%
|
-
|
|
Jan 20
2024
|
Alan List Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,012
+34.0%
|
-
|